The Role of Denosumab in the Modern Treatment of Giant Cell Tumor of Bone

➢ Giant cell tumor of bone (GCTB) is a benign, locally aggressive, osteolytic lesion. Typical treatment involves extended intralesional curettage or en bloc resection. ➢ Denosumab is a fully human monoclonal antibody with inhibitory effects on RANKL (receptor activator of nuclear factor-κB ligand) that has shown early promise as a possible treatment adjuvant for GCTB. ➢ Current clinical trials of denosumab for GCTB have shown >85% clinical, …